28 Years of Patent Activity: Three Phases of Capsule Endoscopy Innovation
Microrobotic capsule endoscopy has generated patent activity continuously from 1998 to 2026 — a span of approximately 28 years captured across 80+ retrieved patent and literature records in this dataset. The field did not emerge uniformly: it progressed through three structurally distinct phases, each defined by a different set of technical problems and leading assignees.
The Foundational Phase (1998–2007) was dominated by Korea Institute of Science and Technology (KIST) and an Italian group (Scuola Superiore di Studi Universitari e di Perfezionamento). KIST filed the core microcapsule-type robot patents — establishing stop/delay control, camera-lighting-transmitter integration, and leg-based locomotion — as early as 2002–2004 across both US and KR jurisdictions. The Italian group filed endoscopic robot patents as early as 1998. Boston Scientific (IL) entered the wireless robotic endoscope space from 2004.
The Development Phase (2007–2015) refined locomotion systems with anti-adhesion coatings, hemispherical head designs, and high-speed mucus-wall traversal. Electromagnetic field-based control appeared prominently, with Chonnam National University introducing precession rotating magnetic fields for wall-contact locomotion in 2013. The University of Colorado filed a notable tread-based patent using PDMS micro-patterned fabrication via soft lithography in 2013.
The Maturity and Therapeutic Convergence Phase (2016–2026) is defined by AI-guided navigation, multi-sensor fusion, and therapeutic payloads. Key signals include Robomed OY’s wireless biopsy capsule (WO, 2022), Massachusetts General Hospital’s autonomous therapeutic capsule (WO, 2025), Fudan University’s multi-channel sensor fusion system (CN, 2025), and INSERM’s ultrasound microdevice tracking patent (JP, 2026) — the most recently dated record in this dataset.
The microrobotic capsule endoscopy patent landscape spans approximately 28 years of activity from 1998 to 2026, derived from 80+ retrieved patent and literature records, and is segmented into three phases: Foundational (1998–2007), Development (2007–2015), and Maturity and Therapeutic Convergence (2016–2026).
Four Core Technology Clusters Driving Capsule Microrobotics
Microrobotic capsule endoscopy innovation clusters around four distinct technical approaches, each addressing the fundamental challenge of controllable, positionally precise locomotion inside mucus-coated, peristalsis-affected luminal environments. Understanding which cluster a patent belongs to is essential for freedom-to-operate analysis and R&D differentiation.
Cluster 1: Mechanical Locomotion — Leg, Inchworm, and Tread Systems
The dominant early locomotion paradigm employs retractable legs or limbs that contact the intestinal wall and generate propulsion through gripping-extension cycles. KIST pioneered the core architecture: a hemispherical-headed capsule whose legs fold and unfold to grip mucus-coated walls, moving by a controlled linear stroke between inner and outer cylinders. A 2012 EP filing from KIST added anti-adhesion coating on the capsule surface for high-speed wall-adhesion locomotion. The University of Colorado’s 2013 US patent introduced PDMS micro-tread fabrication using soft lithography to enhance friction in biological environments, with a motor-geared drive and roller system. A 2023 CN patent from Southern University of Science and Technology Hospital introduced a sinusoidal tail-driven capsule robot where a motor-driven spine actuates caterpillar-track-style locomotion.
Cluster 2: Electromagnetic Field Actuation and External Magnetic Navigation
Multiple assignees have pursued contactless external magnetic field control as an alternative to onboard mechanical actuators, enabling simpler capsule construction while providing steerable propulsion via precession-rotating or gradient magnetic fields. Chonnam National University’s 2013 KR patent introduced a capsule unit with an embedded magnet module driven by an external electromagnetic field generation unit comprising both uniform and gradient magnetic field modules — the precession rotating field causes the microrobot to advance along the wall surface by rotation. Yonsei University’s 2013 KR patent introduced a stator-rotor electromagnetic propulsion mechanism using coil-generated electromagnetic force and counter-rotating dual rotors. The most recent filing in this cluster is from Korea Institute of Medical Microrobotics (2025, KR), integrating movement control and position recognition within a single bed-mounted electromagnetic system.
ENS use externally generated magnetic fields to steer capsules or microrobots without onboard motors. In the capsule endoscopy context, precession-rotating magnetic fields cause an embedded magnet module to advance the capsule along the intestinal wall. This approach eliminates the need for complex onboard mechanical actuators, simplifying capsule construction and reducing device diameter.
Cluster 3: Wireless Communication, Sensing, and Control Architectures
A persistent technology cluster addresses the communication backbone — RF transceivers, wireless control consoles, position feedback, and image transmission — that transforms a passive capsule into a controllable robotic system. Boston Scientific’s 2004 IL patent established the foundational wireless robotic endoscope architecture using electroactive polymer actuators, wireless transceivers, and portable battery power with bidirectional control and sensor data transmission. Chongqing Jinshan Science & Technology’s 2007 IN patent introduced JPEG-compressed image transmission via RF module to a portable recording device with an antenna array. Fudan University’s 2025 CN filing represents the latest generation, fusing image sensor, motion sensor, and environmental sensor data through a dedicated microprocessor fusion module to enable closed-loop, motion-adaptive control.
Cluster 4: Therapeutic Payload and Interventional Capability
Beyond passive imaging, a distinct cluster covers capsules equipped for biopsy, drug delivery, tissue ablation, and intravascular treatment. Robomed OY’s 2022 WO patent covers a capsule robot with an integrated biopsy needle that pierces the outer membrane to sample GI tissue, with the controller managing needle actuation wirelessly. Massachusetts General Hospital’s 2025 WO filing covers autonomous detection and treatment of GI pathology, integrating optical imaging (white light and narrow-band), thermal imaging, and treatment actuation in a single wireless capsule. Roboute’s 2024 JP patent covers a tethered microrobot navigated to target body sites via a remote control unit and wire-sliding flexible element, designed for drug delivery and biological sample collection.
“The 2025 MGH autonomous therapeutic capsule integrates optical imaging, thermal imaging, and treatment actuation in a single wireless ingestible device — removing the need for continuous physician joystick control.”
Map the full capsule endoscopy patent landscape and identify white-space opportunities with PatSnap Eureka.
Explore Patent Data in PatSnap Eureka →In the microrobotic capsule endoscopy patent dataset, locomotion approaches span mechanical leg-based inchworm mechanisms, electromagnetic field-driven rotation, motor-driven tread systems, helical and sinusoidal tail propulsion, and emerging light-actuated microrobot propulsion — with electromagnetic actuation identified as the most commercially viable propulsion pathway for near-term clinical deployment.
Geographic and Assignee Landscape: Korea Leads, China Accelerates
Korea is the most heavily represented jurisdiction in this dataset for core capsule microrobotics, driven almost entirely by public research institutions rather than commercial entities. Korea Institute of Science and Technology (KIST) is the single most prolific assignee, with at least 10 distinct patent records spanning KR, US, JP, CN, and EP jurisdictions filed between 2002 and 2012.
Secondary Korean assignees include Industry Foundation of Chonnam National University (intravascular and capsule endoscope systems), Yonsei University Industry-Academic Cooperation Foundation (electromagnetic propulsion), and Korea Institute of Medical Microrobotics (bed-integrated EM systems, 2025). Japan appears as the second most frequent jurisdiction among retrieved records, but predominantly as a translation and re-filing jurisdiction rather than an origination centre — KIST, Boston Scientific, Covidien, and Roboute all have JP-filed translations of their core patents. Olympus is a notable JP-originating assignee with robotic endoscope positioning and ML-based navigation filings in 2023.
The 2025 CN filing from Fudan University on multi-channel sensor fusion capsule robotics, alongside prior Chongqing Jinshan wireless capsule filings (2007), signals that Chinese institutions are building domestic IP positions that will require monitoring by Western and Korean players for freedom-to-operate analysis in the CN market.
US filings include KIST translations, the University of Colorado’s tread patent, and Korean Institute of Science and Technology colonoscopy micro-robot patents. European coverage includes KIST’s EP filing on the capsule moving system and Golberg’s WO/GB controllable microcapsule robot. Robomed OY (Finland) filed a WO biopsy capsule in 2022, and General Hospital Corporation (MGH, US) filed a WO autonomous therapeutic capsule in 2025. According to WIPO, PCT filings in medical robotics have grown consistently over the past decade, with therapeutic applications representing an increasing share of new applications.
Korea Institute of Science and Technology (KIST) is the single most prolific assignee in the microrobotic capsule endoscopy patent dataset, with at least 10 distinct patent records spanning KR, US, JP, CN, and EP jurisdictions filed between 2002 and 2012. Most of these pre-2012 filings now show inactive legal status, creating an open field for commercialisation of foundational locomotion architectures.
Application Domains: From GI Diagnostics to Vascular Intervention
Gastrointestinal diagnostics is the primary application domain for microrobotic capsule endoscopy, but the dataset reveals a broadening scope that extends to vascular intervention, minimally invasive surgical endoscopy, and AI-guided catheter navigation — each representing a distinct commercialisation pathway with different regulatory and IP considerations.
The overwhelming majority of retrieved patents target the GI tract — specifically the small intestine, large intestine (colon), and stomach — where conventional endoscopy causes discomfort or cannot reach. KIST’s family of microcapsule robots (2002–2012) consistently targets colon and small intestine inspection without mucosal damage. A 2019 literature result from Harvard Medical School and Brigham and Women’s Hospital identifies robotic-assisted surgical endoscopy as the enabler for endoscopic submucosal dissection (ESD), natural orifice transluminal endoscopic surgery (NOTES), and endoscopic suturing in community settings — underscoring the clinical translation pathway.
Vascular and intraluminal therapy represents a second significant application domain. Chonnam National University’s 2009 KR patent covers a microrobot for intravascular therapy, and the same institution filed a guide-wired helical microrobot for mechanical thrombectomy in 2021 (KR) — using electromagnetic navigation-guided helical drilling to remove calcified thrombi, with applications in stroke, cerebral infarction, and peripheral vascular occlusion. Research published by institutions including NEJM and Nature has highlighted minimally invasive endovascular approaches as a priority area for reducing procedural morbidity in stroke intervention.
Minimally invasive surgical endoscopy is addressed by Covidien’s 2023 JP patent on endoluminal robotic (ELR) systems covering multi-arm robotic endoscopic systems for suturing, pressure sensing, and image fusion with haptic feedback. Covidien also filed a 2021 CN patent for a legged crawling microrobot imaging device deployed inside the abdominal cavity for laparoscopic visualisation. Brigham and Women’s Hospital’s 2023 JP patent applies AI navigation models to guide catheter-embedded imaging and spectrometer capsules to GI and airway targets autonomously — representing a convergence of capsule endoscopy and AI-driven robotics that the FDA and regulatory bodies globally are beginning to address through dedicated AI/ML medical device guidance frameworks.
Analyse freedom-to-operate across capsule endoscopy application domains with PatSnap Eureka’s AI-powered patent search.
Run FTO Analysis in PatSnap Eureka →Five Frontier Directions Shaping the Field Through 2026
Analysis of the most recent filings in this dataset (2022–2026) reveals five distinct frontier directions that define where microrobotic capsule endoscopy is heading — and where the next generation of defensible IP will be built.
1. Autonomous and AI-Navigated Capsules. The 2025 WO filing from Massachusetts General Hospital covers a wireless ingestible luminal diagnostic capsule that autonomously treats a condition. The 2023 JP filing from Brigham and Women’s Hospital on AI-powered robotic intestinal tubes applies trained ML models for autonomous anatomy recognition, route planning, and treatment actuation — removing the need for continuous physician joystick control.
2. Multi-Channel Sensor Fusion. Fudan University’s 2025 CN patent covers a capsule robot system based on multi-channel information fusion sensing, fusing image, motion, and environmental sensor data through a dedicated microprocessor fusion module. This architecture enables closed-loop, motion-adaptive control that adjusts to GI tract geometry in real time.
3. Bed-Integrated Electromagnetic Control Platforms. Korea Institute of Medical Microrobotics’ 2025 KR patent integrates movement control and position recognition within a single bed-mounted electromagnetic system — potentially enabling commercial deployment with existing clinical workflows, as the patient bed itself serves as the electromagnetic actuation and localisation platform.
4. Optical and Light-Actuated Microrobot Propulsion. Roboute’s 2024 JP patent introduces an optical-fibre-delivered light signal that activates an actuator zone causing periodic extension and retraction of a propulsion structure. This approach targets ultra-low-Reynolds-number environments such as the brain, but its principles are transferable to GI microrobotics.
5. Ultrasound-Based Microdevice Tracking. INSERM’s 2026 JP patent — the most recently dated record in this dataset — provides real-time ultrasound-based localisation of microdevices within target body parts, displaying their position overlaid on stored ultrasound images. This directly addresses the outstanding clinical challenge of in-vivo capsule location awareness, which is a prerequisite for regulatory clearance of therapeutic capsule robotics.
“INSERM’s 2026 ultrasound microdevice tracking patent is the most recently dated record in this dataset — addressing the outstanding clinical challenge of in-vivo capsule location awareness that stands between therapeutic capsule robotics and regulatory clearance.”
Five frontier directions are identifiable from the most recent microrobotic capsule endoscopy filings (2022–2026): autonomous and AI-navigated capsules, multi-channel sensor fusion, bed-integrated electromagnetic control platforms, optical and light-actuated microrobot propulsion, and ultrasound-based microdevice tracking. The most recently dated patent in this dataset is from INSERM (2026, JP), covering real-time ultrasound-based localisation of microdevices overlaid on stored ultrasound images.
Strategic Implications for IP Teams and R&D Leaders
KIST’s foundational patent portfolio is now largely lapsed or inactive — most pre-2012 US and JP filings show inactive legal status — creating a substantially open field for commercialisation of foundational locomotion architectures. However, any new entrant must differentiate on AI control, sensing integration, or therapeutic payload, not basic locomotion mechanics, as these foundational approaches are now prior art.
Electromagnetic actuation remains the most commercially viable propulsion pathway for near-term clinical deployment, as evidenced by continued investment from Korean public research institutions — Chonnam National University, Yonsei University, and Korea Institute of Medical Microrobotics — and the convergence of bed-integrated EM platforms with position-recognition synchronisation. IP strategists should audit freedom-to-operate specifically around electromagnetic field configurations and gradient control algorithms.
The therapeutic capsule segment is nascent but accelerating. The 2022 Robomed OY biopsy capsule (WO) and the 2025 MGH autonomous treatment capsule (WO) represent the leading edge of a transition from diagnostics-only platforms. R&D teams should prioritise biopsy needle mechanisms, drug-release actuators, and ablation delivery as defensible differentiation vectors. Patent data from EPO and WIPO consistently show that therapeutic device claims attract longer prosecution times and stronger litigation positions than diagnostic-only claims.
China is an emerging origination market, not merely a translation target. The 2025 Fudan University CN filing on sensor fusion capsule robotics, alongside prior Chongqing Jinshan wireless capsule filings, signals that Chinese institutions are building domestic IP positions that will require monitoring by Western and Korean players for freedom-to-operate analysis in the CN market. PatSnap’s IP intelligence platform and R&D intelligence solutions provide continuous monitoring across CN patent databases for exactly this type of emerging assignee activity.
Ultrasound localisation and multi-modal position tracking — as filed by INSERM in 2026 — will become critical infrastructure. Without reliable in-vivo device localisation, therapeutic capsule robotics cannot receive regulatory clearance. IP around real-time microdevice tracking using ultrasound, EM field synchronisation, or AI-based anatomy recognition will be disproportionately strategically valuable in the next commercialisation cycle.